ajh26446-sup-0001-FigureS1.pdfPDF document, 41.9 KB

Figure S1. Flowchart of inclusion and exclusion criteria.

ajh26446-sup-0002-FigureS2.pdfPDF document, 1.5 MB

Figure S2. Logarithmic axis of patient weight (A), TNCs (B), CD34+ cells (C) in the CBT-no ATG group and ATG dose in the PBSCT-ATG group.

ajh26446-sup-0003-FigureS3.pdfPDF document, 527.4 KB

Figure S3. Cumulative incidences of grade II–IV acute GVHD (A), grade III–IV acute GVHD (B), chronic GVHD (C), and extensive chronic GVHD (D) according to HLA mismatch in the PBSCT-ATG group.

ajh26446-sup-0004-FigureS4.pdfPDF document, 631.2 KB

Figure S4. Overall survival (A), relapse (B), non-relapse mortality (C), grade III–IV acute GVHD (D), and extensive chronic GVHD (E) according to the total dose of ATG in the PBSCT-ATG group.

ajh26446-sup-0005-Tables.docxWord 2007 document , 15 KB

Table S1. Cause of death.

Table S2. Viral infection in the CBT-no ATG and the PBSCT-ATG group.

Abbreviations: CBT, cord blood transplantation; ATG, antithymocyte globulin; CBT-no ATG, CBT without ATG; PBSCT, peripheral blood stem-cell transplantation; PBSCT-ATG group, PBSCT using low-dose ATG